Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski(KU Leuven), Sant P. Chawla(Sarcoma Oncology Center), Robert G. Maki(Mount Sinai Medical Center), Antoîne Italiano(Institut Bergonié), Hans Gelderblom(Leiden University Medical Center), Edwin Choy(Massachusetts General Hospital), Giovanni Grignani(Fondazione Piemontese per la Ricerca sul Cancro Onlus), Veridiana Pires de Camargo(Instituto do Câncer do Estado de São Paulo), Sebastian Bauer(University of Duisburg-Essen), Sun Young Rha(Yonsei University), Jean‐Yves Blay(Centre Léon Bérard), Peter Hohenberger(Heidelberg University), David R. D’Adamo(Eisai (United States)), Matthew Guo(Eisai (United States)), Bartosz Chmielowski(UCLA Health), Axel Le Cesne(Institut Gustave Roussy), George D. Demetri(Harvard University), Shreyaskumar Patel(The University of Texas MD Anderson Cancer Center)
Cited by 761Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis